/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES/
QUEBEC CITY, May 17, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Company") (TSXV: OPS) (OTCQX:
OPSSF) is pleased to announce it has completed a non-brokered
private placement for gross proceeds of approximately $5,000,000 led by Lumira Capital LP, a fund
specialized in health and life sciences, with offices in
Toronto, Montreal, Boston and San
Diego. Under the terms of the private placement, the Company
issued a total of 4,761,000 units (the "Units") at a price of
$1.05 per Unit.
Each Unit consists of one common share in the capital of Opsens
and one-half of one common share purchase warrant (each whole
common share purchase warrant, a "Warrant"), with each Warrant
entitling the holder thereof to purchase one common share at a
price of $1.55 within 18 months
from the closing date of the private placement.
The Company intends to use the net proceeds to execute its sales
and marketing strategy for its products for Fractional Flow Reserve
("FFR"), to fund research and product development and to fund its
working capital.
The private placement remains subject to the approval of the TSX
Venture Exchange. All the securities to be issued according to the
private placement will be subject to a four month and one day
restriction period pursuant to the applicable securities
legislation.
This press release does not constitute an offer of securities
for sale in the United States or to "U.S. persons" ("U.S.
persons"), as such term is defined in Regulation S promulgated
under the United States Securities Act of 1933, as amended (the
"U.S. Securities Act"). The securities being offered have not been,
nor will be, registered under the U.S. Securities Act or any state
securities laws, and may not be offered or sold in the United
States or to U.S. persons absent registration or an applicable
exemption from such registration requirements.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Company develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications, such as the monitoring of oil wells and other
demanding industrial applications.
Forward-looking statements contained in this press release
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of
Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE OPSENS INC.